Issue
Date Log
Copyright (c) 2026 Hassan Jaber Hassan Ammash, Hamzah Shuwaier Ali Salwa, Mohammed Muthker M Almutairi, Abdullah Msfer Saad Alosaimi, Hani Muqaybil Alruwaili, Atallah Zafran Altarfawi, Hussain Hassan H Abushaqarah, Talal Ali Alsharari, Abdulrahman Abdulaziz Awad Al-Otaibi, Mansour Ibrahim Ahmed Otudi, Khaled Jumaan Khaled Alghamdi, Ahlam Mohammed Jaradi Tayran

This work is licensed under a Creative Commons Attribution 4.0 International License.
The Role of Emergency Professionals, Nurses and Public Health Professionals in Managing Acute Exacerbations of Chronic Obstructive Pulmonary Disease.
Corresponding Author(s) : Hassan Jaber Hassan Ammash
Saudi Journal of Medicine and Public Health,
Vol. 3 No. 1 (2026)
Abstract
Background: Chronic obstructive pulmonary disease (COPD) is a heterogeneous respiratory disorder characterized by persistent airflow limitation, chronic inflammation, and progressive respiratory impairment. Its clinical presentation and progression vary considerably among patients, creating challenges for diagnosis, treatment selection, and long-term disease control. Emerging evidence supports personalized approaches that address pulmonary and extrapulmonary disease characteristics.
Aim: This review examines recent developments in COPD assessment and management, with particular emphasis on treatable traits, biological therapies, smoking cessation, pulmonary rehabilitation, oxygen therapy, and associated comorbidities.
Methods: A narrative review approach was used to discuss evidence concerning COPD pathophysiology, diagnostic investigations, emerging therapeutic strategies, and multidisciplinary management. Particular attention was given to clinical trials investigating targeted biological agents and interventions addressing modifiable disease characteristics.
Results: COPD assessment increasingly incorporates spirometry, imaging, inflammatory biomarkers, and functional investigations to identify disease phenotypes and support earlier diagnosis. The treatable traits approach provides a personalized framework for managing pulmonary, extrapulmonary, and behavioral factors, including its potential application in pre-COPD. Among biological therapies, dupilumab has demonstrated reductions in moderate or severe exacerbations and improvements in lung function among patients with elevated blood eosinophils. Evidence supporting IL-5 and TSLP pathway inhibitors remains inconsistent, while IL-33-targeted therapies require further investigation. Smoking cessation, pulmonary rehabilitation, and appropriate oxygen therapy remain essential management strategies. Cardiovascular disease, sleep-disordered breathing, obesity, and dysfunctional breathing also require systematic assessment because they influence clinical outcomes and disease burden.
Conclusion: COPD management is evolving toward personalized, multidimensional care. Integrating early diagnosis, treatable traits, targeted therapies, lifestyle interventions, and comorbidity management may improve treatment selection and patient outcomes.
Keywords
Download Citation
Endnote/Zotero/Mendeley (RIS)BibTeX
- 1.“Global Burden of 288 Causes of Death and Life Expectancy Decomposition in 204 Countries and Territories and 811 Subnational Locations, 1990‐2021: A Systematic Analysis for the Global Burden of Disease Study 2021,” Lancet 403 (2024): 2100–2132.
- 2. Mannino D. M., Roberts M. H., Mapel D. W., et al., “National and Local Direct Medical Cost Burden of COPD in the United States From 2016 to 2019 and Projections Through 2029,” Chest 165 (2024): 1093–1106.
- 3. Aaron S. D., Vandemheen K. L., Whitmore G. A., et al., “Early Diagnosis and Treatment of COPD and Asthma—A Randomized, Controlled Trial,” New England Journal of Medicine 390, no. 22 (2024): 2061–2073, 10.1056/NEJMoa2401389.
- 4. Chen Q., Fan Y., Huang K., et al., “Cost‐Effectiveness of Population‐Based Screening for Chronic Obstructive Pulmonary Disease in China: A Simulation Modeling Study,” Lancet Regional Health – Western Pacific 46 (2024): 101065.
- 5. Leung C. C., “Use of Spirometry to Detect Airflow Obstruction,” Respirology 29 (2024): 443–444
- 6. Zhang Y., Gai X., Chu H., Qu J., Li L., and Sun Y., “Prevalence of Non‐Smoking Chronic Obstructive Pulmonary Disease and Its Risk Factors in China: A Systematic Review and Meta‐Analysis,” BMC Public Health 24 (2024): 3010.
- 7. Pandey A. K., Verma A. K., Singh A., et al., “The Severity of Non‐Smoking Chronic Obstructive Pulmonary Disease Is Correlated With Biomass Fuel Exposure and COPD Assessment Test Score,” Lung India 41 (2024): 251–258.
- 8. Rentschler J. and Leonova N., “Global Air Pollution Exposure and Poverty,” Nature Communications 14 (2023): 4432.
- 9. Ma S., Cheng D., Tang Y., et al., “Investigation of Oxidative Potential of Fresh and O(3)‐aging PM(2.5) From Various Emission Sources Across Urban and Rural Regions,” Journal of Environmental Sciences 151 (2025): 608–615.
- 10. Chen J., Braun D., Christidis T., et al., “Long‐Term Exposure to Low‐Level PM2.5 and Mortality: Investigation of Heterogeneity by Harmonizing Analyses in Large Cohort Studies in Canada, United States, and Europe,” Environmental Health Perspectives 131 (2023): 127003.
- 11. Wei T., Chen C., Yang Y., et al., “Associations Between Short‐Term Exposure to Ambient Air Pollution and Lung Function in Adults,” Journal of Exposure Science & Environmental Epidemiology 34 (2024): 886–894.
- 12. Lee H. W., Lee H. J., Oh S., Lee J. K., Heo E. Y., and Kim D. K., “Combined Effect of Changes in NO(2), O(3), PM(2.5), SO(2) and CO Concentrations on Small Airway Dysfunction,” Respirology 29 (2024): 379–386.
- 13. Yang I. A., Jenkins C. R., and Salvi S. S., “Chronic Obstructive Pulmonary Disease in Never‐Smokers: Risk Factors, Pathogenesis, and Implications for Prevention and Treatment,” Lancet Respiratory Medicine 10 (2022): 497–511.
- 14. Vaughan A., Stevanovic S., Jafari M., et al., “Primary Human Bronchial Epithelial Cell Responses to Diesel and Biodiesel Emissions at an Air‐Liquid Interface,” Toxicology In Vitro 57 (2019): 67–75.
- 15. Vaughan A., Stevanovic S., Jafari M., et al., “The Effect of Diesel Emission Exposure on Primary Human Bronchial Epithelial Cells From a COPD Cohort: N‐Acetylcysteine as a Potential Protective Intervention,” Environmental Research 170 (2019): 194–202.
- 16. Guo X., Yang S., Zhu H., et al., “Involvement of M2 Macrophages Polarization in PM2.5‐Induced COPD by Upregulating MMP12 via IL4/STAT6 Pathway,” Ecotoxicology and Environmental Safety 283 (2024): 116793.
- 17. Cheng P. P., Yu F., Chen S. J., et al., “PM2.5 Exposure‐Induced Senescence‐Associated Secretory Phenotype in Airway Smooth Muscle Cells Contributes to Airway Remodeling,” Environmental Pollution 347 (2024): 123674.
- 18. Li S., Qu L., Zhou L., et al., “Biomass Fuels Related‐PM(2.5) Promotes Lung Fibroblast‐Myofibroblast Transition Through PI3K/AKT/TRPC1 Pathway,” Ecotoxicology and Environmental Safety 276 (2024): 116309.
- 19. Niu Y., Zhang L., Guo S., and Wu S., “In Vivo and In Vitro Models of PM2.5 Induced COPD: Focus on the Role of RTA‐408,” International Journal of Chronic Obstructive Pulmonary Disease 19 (2024): 2239–2257.
- 20. Barnes P. J., “Inflammatory Endotypes in COPD,” Allergy 74 (2019): 1249–1256.
- 21. Fraughen D. D., Ghosh A. J., Hobbs B. D., et al., “Augmentation Therapy for Severe Alpha‐1 Antitrypsin Deficiency Improves Survival and Is Decoupled From Spirometric Decline‐A Multinational Registry Analysis,” American Journal of Respiratory and Critical Care Medicine 208 (2023): 964–974.
- 22. Liu G., Tiotiu A., and Hansbro P. M., “Mast Cell Chymase‐1 and Tryptases: Therapeutic Targets for COPD?,” Expert Opinion on Therapeutic Targets 29 (2025): 9–12
- 23. Barnes P. J., “Inflammatory Mechanisms in Patients With Chronic Obstructive Pulmonary Disease,” Journal of Allergy and Clinical Immunology 138 (2016): 16–27.
- 24. Appleton L. K., Hanania N. A., and Adrish M., “Personalized COPD Care: The Future of Precision‐Based Therapies,” Journal of Clinical Medicine 13, no. 21 (2024): 6339, 10.3390/jcm13216339.
- 25. Bafadhel M., Peterson S., De Blas M. A., et al., “Predictors of Exacerbation Risk and Response to Budesonide in Patients With Chronic Obstructive Pulmonary Disease: A Post‐Hoc Analysis of Three Randomised Trials,” Lancet Respiratory Medicine 6 (2018): 117–126.
- 26. Cabrera López C., Sánchez Santos A., Lemes Castellano A., et al., “Eosinophil Subtypes in Adults With Asthma and Adults With Chronic Obstructive Pulmonary Disease,” American Journal of Respiratory and Critical Care Medicine 208 (2023): 155–162.
- 27. Sunata K., Miyata J., Kawashima Y., et al., “Inflammatory Profile of Eosinophils in Asthma‐COPD Overlap and Eosinophilic COPD: A Multi‐Omics Study,” Frontiers in Immunology 15 (2024): 1445769.
- 28. Leung C., Park H. Y., Li X., et al., “Transcriptomic Profiling of the Airway Epithelium in COPD Links Airway Eosinophilia to Type 2 Inflammation and Corticosteroid Response,” European Respiratory Journal 65 (2025): 2401875.
- 29. Hobbs B. D., Morrow J. D., Wang X. W., et al., “Identifying Chronic Obstructive Pulmonary Disease From Integrative Omics and Clustering in Lung Tissue,” BMC Pulmonary Medicine 23, no. 1 (2023): 115, 10.1186/s12890-023-02389-5.
- 30. Moll M. and McDonough J., “Piece of Cake: Slicing Through the Complex Layers of Chronic Obstructive Pulmonary Disease With Lung Tissue Network Analysis,” American Journal of Respiratory and Critical Care Medicine 210 (2024): 1174–1176.
- 31. Olvera N., Sánchez‐Valle J., Núñez‐Carpintero I., et al., “Lung Tissue Multilayer Network Analysis Uncovers the Molecular Heterogeneity of Chronic Obstructive Pulmonary Disease,” American Journal of Respiratory and Critical Care Medicine 210 (2024): 1219–1229.
- 32. Stanojevic S., Kaminsky D. A., Miller M. R., et al., “ERS/ATS Technical Standard on Interpretive Strategies for Routine Lung Function Tests,” European Respiratory Journal 60 (2022): 2101499.
- 33. Cadham C. J., Oh H., Han M. K., et al., “The Prevalence and Mortality Risks of PRISm and COPD in the United States From NHANES 2007‐2012,” Respiratory Research 25, no. 1 (2024): 208, 10.1186/s12931-024-02841-y.
- 34. Tan D. J., Lodge C. J., Walters E. H., et al., “Can we Use Lung Function Thresholds and Respiratory Symptoms to Identify Pre‐Chronic Obstructive Pulmonary Disease? A Prospective, Population‐Based Cohort Study,” American Journal of Respiratory and Critical Care Medicine 209 (2024): 1431–1440
- 35. Lam A. H. S., Alhajri S. A., Potts J., et al., “Optimal Spirometry Thresholds for the Prediction of Chronic Airflow Obstruction: A Multinational Longitudinal Study,” ERJ Open Research 11 (2025): 00624–2024.
- 36. Kogo M., Sato S., Muro S., et al., “Longitudinal Changes and Association of Respiratory Symptoms With Preserved Ratio Impaired Spirometry (PRISm): The Nagahama Study,” Annals of the American Thoracic Society 20 (2023): 1578–1586.
- 37. Petrie K., Abramson M. J., and George J., “Smoking, Respiratory Symptoms, Lung Function and Life Expectancy: A Longitudinal Study of Ageing,” Respirology 29 (2024): 471–478.
- 38. Ritchie A. I., Donaldson G. C., Hoffman E. A., et al., “Structural Predictors of Lung Function Decline in Young Smokers With Normal Spirometry,” American Journal of Respiratory and Critical Care Medicine 209 (2024): 1208–1218.
- 39. Chaudhary M. F. A., Awan H. A., Gerard S. E., et al., “Deep Learning Estimation of Small Airways Disease From Inspiratory Chest CT: Clinical Validation, Repeatability, and Associations With Adverse Clinical Outcomes in COPD,” American Journal of Respiratory and Critical Care Medicine (2025), 10.1164/rccm.202409-1847OC.
- 40. Dunican E. M., Elicker B. M., Gierada D. S., et al., “Mucus Plugs in Patients With Asthma Linked to Eosinophilia and Airflow Obstruction,” Journal of Clinical Investigation 128 (2018): 997–1009.
- 41. Flynn C. and Brightling C., “Picture This: The Future of Imaging Biomarkers in COPD,” Respirology 29 (2024): 932–934.
- 42. Dunican E. M., Elicker B. M., Henry T., et al., “Mucus Plugs and Emphysema in the Pathophysiology of Airflow Obstruction and Hypoxemia in Smokers,” American Journal of Respiratory and Critical Care Medicine 203 (2021): 957–968.
- 43. Mettler S. K., Nath H. P., Grumley S., et al., “Silent Airway Mucus Plugs in COPD and Clinical Implications,” Chest 166 (2024): 1010–1019.
- 44. Tanabe N., Shimizu K., Shima H., et al., “Computed Tomography Mucus Plugs and Airway Tree Structure in Patients With Chronic Obstructive Pulmonary Disease: Associations With Airflow Limitation, Health‐Related Independence and Mortality,” Respirology 29 (2024): 951–961.
- 45. Wan E., Yen A., Elalami R., et al., “Airway Mucus Plugs on Chest Computed Tomography Are Associated With Exacerbations in COPD,” American Journal of Respiratory and Critical Care Medicine 211 (2025): 814–822, 10.1164/rccm.202403-0632OC.
- 46. Li X., Feng S., Yang Y., et al., “Association Between Airway Mucus Plugs and Risk of Moderate‐To‐Severe Exacerbations in COPD Patients:Results From a Chinese Prospective Cohort Study,” Chest (2025), 10.1016/j.chest.2025.03.026
- 47. Serajeddini H., Eddy R. L., Licskai C., McCormack D. G., and Parraga G., “FEV(1) and MRI Ventilation Defect Reversibility in Asthma and COPD,” European Respiratory Journal 55 (2020): 1901947, 10.1183/13993003.01947-2019.
- 48. Elbehairy A. F., Marshall H., Naish J. H., et al., “Advances in COPD Imaging Using CT and MRI: Linkage With Lung Physiology and Clinical Outcomes,” European Respiratory Journal 63 (2024): 2301010.
- 49. Wang Z., Bier E. A., Swaminathan A., et al., “Diverse Cardiopulmonary Diseases Are Associated With Distinct Xenon Magnetic Resonance Imaging Signatures,” European Respiratory Journal 54 (2019): 1900831.
- 50. Meldrum O. W., Donaldson G. C., Narayana J. K., et al., “Accelerated Lung Function Decline and Mucus‐Microbe Evolution in Chronic Obstructive Pulmonary Disease,” American Journal of Respiratory and Critical Care Medicine 210, no. 3 (2024): 298–310, 10.1164/rccm.202306-1060OC.
- 51. van Rossem I., Hanon S., Verbanck S., and Vanderhelst E., “Blood Eosinophil Counts in Chronic Obstructive Pulmonary Disease: Adding Within‐Day Variability to the Equation,” American Journal of Respiratory and Critical Care Medicine 205 (2022): 727–729.
- 52. Van Rossem I., Hanon S., Vansintejan J., Verbanck S., and Vanderhelst E., “Is Fractional Exhaled Nitric Oxide Ready to Be a Biomarker? Within‐Day Variability in Stable COPD,” Respirology 29, no. 9 (2024): 835–837, 10.1111/resp.14786.
- 53. Bhatt S. P., Rabe K. F., Hanania N. A., et al., “Dupilumab for COPD With Type 2 Inflammation Indicated by Eosinophil Counts,” New England Journal of Medicine 389 (2023): 205–214.
- 54. Bhatt S. P., Rabe K. F., Hanania N. A., et al., “Dupilumab for COPD With Blood Eosinophil Evidence of Type 2 Inflammation,” New England Journal of Medicine 390 (2024): 2274–2283.
- 55. McDonald V. M. and Gibson P. G., “Treatable Traits‐Where We Are, Where We Are Headed,” Respirology 29 (2024): 539–541.
- 56. McDonald V. M. and Holland A. E., “Treatable Traits Models of Care,” Respirology 29 (2024): 24–35.
- 57. Srikanthan K., Kistemaker L., Slebos D.‐J., et al., “Targeted Lung Denervation Modulates the Mucosal Epithelial Transcriptome in COPD,” ERJ Open Research 8, no. 4 (2022): 00146–02022, 10.1183/23120541.00146-2022
- 58. Hartman J. E., Herth F. J. F., Shah P., et al., “Computed Tomographic Airway Morphology After Targeted Lung Denervation Treatment in COPD,” Respiratory Medicine 206 (2023): 107059, 10.1016/j.rmed.2022.107059.
- 59. Dharmage S. C., Faner R., and Agustí A., “Treatable Traits in Pre‐COPD: Time to Extend the Treatable Traits Paradigm Beyond Established Disease,” Respirology 29 (2024): 551–562.
- 60. Pavord I. D., Chanez P., Criner G. J., et al., “Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease,” New England Journal of Medicine 377 (2017): 1613–1629.
- 61. Criner G. J., Celli B. R., Brightling C. E., et al., “Benralizumab for the Prevention of COPD Exacerbations,” New England Journal of Medicine 381 (2019): 1023–1034.
- 62. Haldar K., Mistry V., Richardson M., et al., “Effect of Benralizumab Treatment on the Airway Microbiome in COPD,” ERJ Open Research 11, no. 2 (2025): 00802‐2024, 10.1183/23120541.00802-2024.
- 63. Ramakrishnan S., Russell R. E. K., Mahmood H. R., et al., “Treating Eosinophilic Exacerbations of Asthma and COPD With Benralizumab (ABRA): A Double‐Blind, Double‐Dummy, Active Placebo‐Controlled Randomised Trial,” Lancet Respiratory Medicine 13 (2025): 59–68.
- 64. Bhatt S. P., Rabe K. F., Hanania N. A., et al., “Dupilumab for Chronic Obstructive Pulmonary Disease With Type 2 Inflammation: A Pooled Analysis of Two Phase 3, Randomised, Double‐Blind, Placebo‐Controlled Trials,” Lancet Respiratory Medicine 13 (2025): 234–243.
- 65. Singh D., Brightling C. E., Rabe K. F., et al., “Efficacy and Safety of Tezepelumab Versus Placebo in Adults With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COURSE): A Randomised, Placebo‐Controlled, Phase 2a Trial,” Lancet Respiratory Medicine 13, no. 1 (2025): 47–58, 10.1016/S2213-2600(24)00324-2.
- 66. Rabe K. F., Celli B. R., Wechsler M. E., et al., “Safety and Efficacy of Itepekimab in Patients With Moderate‐To‐Severe COPD: A Genetic Association Study and Randomised, Double‐Blind, Phase 2a Trial,” Lancet Respiratory Medicine 9 (2021): 1288–1298.
- 67. Yousuf A. J., Mohammed S., Carr L., et al., “Astegolimab, an Anti‐ST2, in Chronic Obstructive Pulmonary Disease (COPD‐ST2OP): A Phase 2a, Placebo‐Controlled Trial,” Lancet Respiratory Medicine 10 (2022): 469–477.
- 68. Singh D., Guller P., Reid F., et al., “A Phase 2a Trial of the IL‐33 mAb Tozorakimab in Patients With COPD: FRONTIER‐4,” European Respiratory Journal (2025): 2402231, 10.1183/13993003.02231-2024.
- 69. Wang Z., Qiu Y., Ji X., and Dong L., “Effects of Smoking Cessation on Individuals With COPD: A Systematic Review and Meta‐Analysis,” Frontiers in Public Health 12 (2024): 1433269.
- 70. Siegel S. D., Lerman C., Flitter A., and Schnoll R. A., “The Use of the Nicotine Metabolite Ratio as a Biomarker to Personalize Smoking Cessation Treatment: Current Evidence and Future Directions,” Cancer Prevention Research 13 (2020): 261–272.
- 71. Qin R., Liu Z., Cheng A.‐q., et al., “Efficacy of Varenicline or Bupropion and Its Association With Nicotine Metabolite Ratio Among Smokers With COPD,” Respirology 29, no. 6 (2024): 479–488, 10.1111/resp.14702.
- 72. Cinciripini P. M., Green C. E., Shete S., et al., “Smoking Cessation After Initial Treatment Failure With Varenicline or Nicotine Replacement: A Randomized Clinical Trial,” Journal of the American Medical Association 331 (2024): 1722–1731.
- 73. Rungruanghiranya S., Tulatamakit S., Chittawatanarat K., et al., “Efficacy and Safety of Cytisine Versus Nortriptyline for Smoking Cessation: A Multicentre, Randomized, Double‐Blinded and Placebo‐Controlled Trial,” Respirology 29 (2024): 880–887.
- 74. Livingstone‐Banks J., Fanshawe T. R., Thomas K. H., et al., “Nicotine Receptor Partial Agonists for Smoking Cessation,” Cochrane Database of Systematic Reviews 5, no. 5 (2023): Cd006103, 10.1002/14651858.CD006103.pub8.
- 75. Puljević C., Stjepanović D., Meciar I., et al., “Systematic Review and Meta‐Analyses of Cytisine to Support Tobacco Cessation,” Addiction 119 (2024): 1713–1725.
- 76. Auer R., Schoeni A., Humair J. P., et al., “Electronic Nicotine‐Delivery Systems for Smoking Cessation,” New England Journal of Medicine 390 (2024): 601–610.
- 77. Allbright K., Villandre J., Crotty Alexander L. E., et al., “The Paradox of the Safer Cigarette: Understanding the Pulmonary Effects of Electronic Cigarettes,” European Respiratory Journal 63 (2024): 2301494
- 78. Caponnetto P., Campagna D., Ahluwalia J. S., et al., “Varenicline and Counseling for Vaping Cessation: A Double‐Blind, Randomized, Parallel‐Group, Placebo‐Controlled Trial,” BMC Medicine 21 (2023): 220.
- 79. Caponnetto P., Spicuzza L., Campagna D., et al., “Varenicline for Smoking Cessation in Individuals Who Smoke Cigarettes and Use Electronic Cigarettes: A Double‐Blind, Randomised, Placebo‐Controlled Phase 3 Trial,” EClinicalMedicine 66 (2023): 102316.
- 80. Ran B., Zhang Y., Wu Y., and Wen F., “Association Between Depression and COPD: Results From the NHANES 2013‐2018 and a Bidirectional Mendelian Randomization Analysis,” Expert Review of Respiratory Medicine 17 (2023): 1061–1068.
- 81. Sharma P., Scheffer K., Louis M., Aitken C. R., Adams L., and Morris N. R., “Effect of Experimental Modulation of Mood on Exertional Dyspnoea in Chronic Obstructive Pulmonary Disease,” Respirology 29 (2024): 201–208.
- 82. Pascoe A. and Smallwood N., “Breaking the Spiral: How Negative Mood Can Fuel Exertional Breathlessness in People With Chronic Obstructive Pulmonary Disease,” Respirology 29 (2024): 193–194.
- 83. Higginson I. J., Brown S. T., Oluyase A. O., et al., “Mirtazapine to Alleviate Severe Breathlessness in Patients With COPD or Interstitial Lung Diseases (BETTER‐B): An International, Multicentre, Double‐Blind, Randomised, Placebo‐Controlled, Phase 3 Mixed‐Method Trial,” Lancet Respiratory Medicine 12 (2024): 763–774.
- 84. Meneses‐Echavez J. F., Chavez Guapo N., Loaiza‐Betancur A. F., Machado A., and Bidonde J., “Pulmonary Rehabilitation for Acute Exacerbations of COPD: A Systematic Review,” Respiratory Medicine 219 (2023): 107425.
- 85. Muñoz Montiel A., Ruiz‐Esteban P., Del Doménech Río A., Valdivielso P., Sánchez Chaparro M., and Olveira C., “The Effect of Pulmonary Rehabilitation on Cardiovascular Risk, Oxidative Stress and Systemic Inflammation in Patients With COPD,” Respiratory Medicine 232 (2024): 107740.
- 86. van der Molen M. C., Posthuma R., Hartman J. E., et al., “Impact and Timing of Pulmonary Rehabilitation in Patients Undergoing Bronchoscopic Lung Volume Reduction With Endobronchial Valves: A Multicentre Randomized Controlled Trial in Patients With Severe Emphysema,” Respirology 29 (2024): 694–703.
- 87. Strange C. and Talley M., “Winning the Tour de France With Endobronchial Valve Therapy Without Pulmonary Rehabilitation,” Respirology 29 (2024): 651–652.
- 88. Cranston J. M., Crockett A. J., Moss J. R., and Alpers J. H., “Domiciliary Oxygen for Chronic Obstructive Pulmonary Disease,” Cochrane Database of Systematic Reviews 2005 (2005): Cd001744.
- 89. García‐Talavera I., Figueira‐Gonçalves J. M., Esteban C., et al., “Oxygen Therapy Could Improve Survival in Patients With Early Desaturation in the 6‐Minute Walk Test: A Post Hoc Analysis,” Respirology 29 (2024): 340–343.
- 90. Cobb K., Kenyon J., Lu J., et al., “COPD Is Associated With Increased Cardiovascular Disease Risk Independent of Phenotype,” Respirology 29 (2024): 1047–1057.
- 91. Cochrane B., “COPD: The Forgotten Cardiovascular Risk,” Respirology 29 (2024): 1013–1014.
- 92. Marin J. M., Soriano J. B., Marin‐Oto M., et al., “Sleep‐Disordered Breathing in Patients With COPD: Prevalence and Outcomes,” Annals of the American Thoracic Society (2025), 10.1513/AnnalsATS.202501-030OC
- 93. Zhang X., Gray A. R., and Hancox R. J., “Predictors of Lung Function in Early Adulthood: A Population‐Based Cohort Study,” Respirology 29 (2024): 897–904.
- 94. Garcia‐Aymerich J. and Peralta G. P., “Childhood Physical Inactivity and Excess Weight: Two Potentially Modifiable Risk Factors for COPD,” Respirology 29 (2024): 856–857.
- 95. Ruane L. E., Denton E., Bardin P. G., and Leong P., “Dysfunctional Breathing or Breathing Pattern Disorder: New Perspectives on a Common but Clandestine Cause of Breathlessness,” Respirology 29 (2024): 863–866.
- 96. van Dixhoorn J. and Duivenvoorden H. J., “Efficacy of Nijmegen Questionnaire in Recognition of the Hyperventilation Syndrome,” Journal of Psychosomatic Research 29 (1985): 199–206.
- 97. Law N., Ruane L. E., Low K., Hamza K., and Bardin P. G., “Dysfunctional Breathing Is More Frequent in Chronic Obstructive Pulmonary Disease Than in Asthma and in Health,” Respiratory Physiology & Neurobiology 247 (2018): 20–23
References
1.“Global Burden of 288 Causes of Death and Life Expectancy Decomposition in 204 Countries and Territories and 811 Subnational Locations, 1990‐2021: A Systematic Analysis for the Global Burden of Disease Study 2021,” Lancet 403 (2024): 2100–2132.
2. Mannino D. M., Roberts M. H., Mapel D. W., et al., “National and Local Direct Medical Cost Burden of COPD in the United States From 2016 to 2019 and Projections Through 2029,” Chest 165 (2024): 1093–1106.
3. Aaron S. D., Vandemheen K. L., Whitmore G. A., et al., “Early Diagnosis and Treatment of COPD and Asthma—A Randomized, Controlled Trial,” New England Journal of Medicine 390, no. 22 (2024): 2061–2073, 10.1056/NEJMoa2401389.
4. Chen Q., Fan Y., Huang K., et al., “Cost‐Effectiveness of Population‐Based Screening for Chronic Obstructive Pulmonary Disease in China: A Simulation Modeling Study,” Lancet Regional Health – Western Pacific 46 (2024): 101065.
5. Leung C. C., “Use of Spirometry to Detect Airflow Obstruction,” Respirology 29 (2024): 443–444
6. Zhang Y., Gai X., Chu H., Qu J., Li L., and Sun Y., “Prevalence of Non‐Smoking Chronic Obstructive Pulmonary Disease and Its Risk Factors in China: A Systematic Review and Meta‐Analysis,” BMC Public Health 24 (2024): 3010.
7. Pandey A. K., Verma A. K., Singh A., et al., “The Severity of Non‐Smoking Chronic Obstructive Pulmonary Disease Is Correlated With Biomass Fuel Exposure and COPD Assessment Test Score,” Lung India 41 (2024): 251–258.
8. Rentschler J. and Leonova N., “Global Air Pollution Exposure and Poverty,” Nature Communications 14 (2023): 4432.
9. Ma S., Cheng D., Tang Y., et al., “Investigation of Oxidative Potential of Fresh and O(3)‐aging PM(2.5) From Various Emission Sources Across Urban and Rural Regions,” Journal of Environmental Sciences 151 (2025): 608–615.
10. Chen J., Braun D., Christidis T., et al., “Long‐Term Exposure to Low‐Level PM2.5 and Mortality: Investigation of Heterogeneity by Harmonizing Analyses in Large Cohort Studies in Canada, United States, and Europe,” Environmental Health Perspectives 131 (2023): 127003.
11. Wei T., Chen C., Yang Y., et al., “Associations Between Short‐Term Exposure to Ambient Air Pollution and Lung Function in Adults,” Journal of Exposure Science & Environmental Epidemiology 34 (2024): 886–894.
12. Lee H. W., Lee H. J., Oh S., Lee J. K., Heo E. Y., and Kim D. K., “Combined Effect of Changes in NO(2), O(3), PM(2.5), SO(2) and CO Concentrations on Small Airway Dysfunction,” Respirology 29 (2024): 379–386.
13. Yang I. A., Jenkins C. R., and Salvi S. S., “Chronic Obstructive Pulmonary Disease in Never‐Smokers: Risk Factors, Pathogenesis, and Implications for Prevention and Treatment,” Lancet Respiratory Medicine 10 (2022): 497–511.
14. Vaughan A., Stevanovic S., Jafari M., et al., “Primary Human Bronchial Epithelial Cell Responses to Diesel and Biodiesel Emissions at an Air‐Liquid Interface,” Toxicology In Vitro 57 (2019): 67–75.
15. Vaughan A., Stevanovic S., Jafari M., et al., “The Effect of Diesel Emission Exposure on Primary Human Bronchial Epithelial Cells From a COPD Cohort: N‐Acetylcysteine as a Potential Protective Intervention,” Environmental Research 170 (2019): 194–202.
16. Guo X., Yang S., Zhu H., et al., “Involvement of M2 Macrophages Polarization in PM2.5‐Induced COPD by Upregulating MMP12 via IL4/STAT6 Pathway,” Ecotoxicology and Environmental Safety 283 (2024): 116793.
17. Cheng P. P., Yu F., Chen S. J., et al., “PM2.5 Exposure‐Induced Senescence‐Associated Secretory Phenotype in Airway Smooth Muscle Cells Contributes to Airway Remodeling,” Environmental Pollution 347 (2024): 123674.
18. Li S., Qu L., Zhou L., et al., “Biomass Fuels Related‐PM(2.5) Promotes Lung Fibroblast‐Myofibroblast Transition Through PI3K/AKT/TRPC1 Pathway,” Ecotoxicology and Environmental Safety 276 (2024): 116309.
19. Niu Y., Zhang L., Guo S., and Wu S., “In Vivo and In Vitro Models of PM2.5 Induced COPD: Focus on the Role of RTA‐408,” International Journal of Chronic Obstructive Pulmonary Disease 19 (2024): 2239–2257.
20. Barnes P. J., “Inflammatory Endotypes in COPD,” Allergy 74 (2019): 1249–1256.
21. Fraughen D. D., Ghosh A. J., Hobbs B. D., et al., “Augmentation Therapy for Severe Alpha‐1 Antitrypsin Deficiency Improves Survival and Is Decoupled From Spirometric Decline‐A Multinational Registry Analysis,” American Journal of Respiratory and Critical Care Medicine 208 (2023): 964–974.
22. Liu G., Tiotiu A., and Hansbro P. M., “Mast Cell Chymase‐1 and Tryptases: Therapeutic Targets for COPD?,” Expert Opinion on Therapeutic Targets 29 (2025): 9–12
23. Barnes P. J., “Inflammatory Mechanisms in Patients With Chronic Obstructive Pulmonary Disease,” Journal of Allergy and Clinical Immunology 138 (2016): 16–27.
24. Appleton L. K., Hanania N. A., and Adrish M., “Personalized COPD Care: The Future of Precision‐Based Therapies,” Journal of Clinical Medicine 13, no. 21 (2024): 6339, 10.3390/jcm13216339.
25. Bafadhel M., Peterson S., De Blas M. A., et al., “Predictors of Exacerbation Risk and Response to Budesonide in Patients With Chronic Obstructive Pulmonary Disease: A Post‐Hoc Analysis of Three Randomised Trials,” Lancet Respiratory Medicine 6 (2018): 117–126.
26. Cabrera López C., Sánchez Santos A., Lemes Castellano A., et al., “Eosinophil Subtypes in Adults With Asthma and Adults With Chronic Obstructive Pulmonary Disease,” American Journal of Respiratory and Critical Care Medicine 208 (2023): 155–162.
27. Sunata K., Miyata J., Kawashima Y., et al., “Inflammatory Profile of Eosinophils in Asthma‐COPD Overlap and Eosinophilic COPD: A Multi‐Omics Study,” Frontiers in Immunology 15 (2024): 1445769.
28. Leung C., Park H. Y., Li X., et al., “Transcriptomic Profiling of the Airway Epithelium in COPD Links Airway Eosinophilia to Type 2 Inflammation and Corticosteroid Response,” European Respiratory Journal 65 (2025): 2401875.
29. Hobbs B. D., Morrow J. D., Wang X. W., et al., “Identifying Chronic Obstructive Pulmonary Disease From Integrative Omics and Clustering in Lung Tissue,” BMC Pulmonary Medicine 23, no. 1 (2023): 115, 10.1186/s12890-023-02389-5.
30. Moll M. and McDonough J., “Piece of Cake: Slicing Through the Complex Layers of Chronic Obstructive Pulmonary Disease With Lung Tissue Network Analysis,” American Journal of Respiratory and Critical Care Medicine 210 (2024): 1174–1176.
31. Olvera N., Sánchez‐Valle J., Núñez‐Carpintero I., et al., “Lung Tissue Multilayer Network Analysis Uncovers the Molecular Heterogeneity of Chronic Obstructive Pulmonary Disease,” American Journal of Respiratory and Critical Care Medicine 210 (2024): 1219–1229.
32. Stanojevic S., Kaminsky D. A., Miller M. R., et al., “ERS/ATS Technical Standard on Interpretive Strategies for Routine Lung Function Tests,” European Respiratory Journal 60 (2022): 2101499.
33. Cadham C. J., Oh H., Han M. K., et al., “The Prevalence and Mortality Risks of PRISm and COPD in the United States From NHANES 2007‐2012,” Respiratory Research 25, no. 1 (2024): 208, 10.1186/s12931-024-02841-y.
34. Tan D. J., Lodge C. J., Walters E. H., et al., “Can we Use Lung Function Thresholds and Respiratory Symptoms to Identify Pre‐Chronic Obstructive Pulmonary Disease? A Prospective, Population‐Based Cohort Study,” American Journal of Respiratory and Critical Care Medicine 209 (2024): 1431–1440
35. Lam A. H. S., Alhajri S. A., Potts J., et al., “Optimal Spirometry Thresholds for the Prediction of Chronic Airflow Obstruction: A Multinational Longitudinal Study,” ERJ Open Research 11 (2025): 00624–2024.
36. Kogo M., Sato S., Muro S., et al., “Longitudinal Changes and Association of Respiratory Symptoms With Preserved Ratio Impaired Spirometry (PRISm): The Nagahama Study,” Annals of the American Thoracic Society 20 (2023): 1578–1586.
37. Petrie K., Abramson M. J., and George J., “Smoking, Respiratory Symptoms, Lung Function and Life Expectancy: A Longitudinal Study of Ageing,” Respirology 29 (2024): 471–478.
38. Ritchie A. I., Donaldson G. C., Hoffman E. A., et al., “Structural Predictors of Lung Function Decline in Young Smokers With Normal Spirometry,” American Journal of Respiratory and Critical Care Medicine 209 (2024): 1208–1218.
39. Chaudhary M. F. A., Awan H. A., Gerard S. E., et al., “Deep Learning Estimation of Small Airways Disease From Inspiratory Chest CT: Clinical Validation, Repeatability, and Associations With Adverse Clinical Outcomes in COPD,” American Journal of Respiratory and Critical Care Medicine (2025), 10.1164/rccm.202409-1847OC.
40. Dunican E. M., Elicker B. M., Gierada D. S., et al., “Mucus Plugs in Patients With Asthma Linked to Eosinophilia and Airflow Obstruction,” Journal of Clinical Investigation 128 (2018): 997–1009.
41. Flynn C. and Brightling C., “Picture This: The Future of Imaging Biomarkers in COPD,” Respirology 29 (2024): 932–934.
42. Dunican E. M., Elicker B. M., Henry T., et al., “Mucus Plugs and Emphysema in the Pathophysiology of Airflow Obstruction and Hypoxemia in Smokers,” American Journal of Respiratory and Critical Care Medicine 203 (2021): 957–968.
43. Mettler S. K., Nath H. P., Grumley S., et al., “Silent Airway Mucus Plugs in COPD and Clinical Implications,” Chest 166 (2024): 1010–1019.
44. Tanabe N., Shimizu K., Shima H., et al., “Computed Tomography Mucus Plugs and Airway Tree Structure in Patients With Chronic Obstructive Pulmonary Disease: Associations With Airflow Limitation, Health‐Related Independence and Mortality,” Respirology 29 (2024): 951–961.
45. Wan E., Yen A., Elalami R., et al., “Airway Mucus Plugs on Chest Computed Tomography Are Associated With Exacerbations in COPD,” American Journal of Respiratory and Critical Care Medicine 211 (2025): 814–822, 10.1164/rccm.202403-0632OC.
46. Li X., Feng S., Yang Y., et al., “Association Between Airway Mucus Plugs and Risk of Moderate‐To‐Severe Exacerbations in COPD Patients:Results From a Chinese Prospective Cohort Study,” Chest (2025), 10.1016/j.chest.2025.03.026
47. Serajeddini H., Eddy R. L., Licskai C., McCormack D. G., and Parraga G., “FEV(1) and MRI Ventilation Defect Reversibility in Asthma and COPD,” European Respiratory Journal 55 (2020): 1901947, 10.1183/13993003.01947-2019.
48. Elbehairy A. F., Marshall H., Naish J. H., et al., “Advances in COPD Imaging Using CT and MRI: Linkage With Lung Physiology and Clinical Outcomes,” European Respiratory Journal 63 (2024): 2301010.
49. Wang Z., Bier E. A., Swaminathan A., et al., “Diverse Cardiopulmonary Diseases Are Associated With Distinct Xenon Magnetic Resonance Imaging Signatures,” European Respiratory Journal 54 (2019): 1900831.
50. Meldrum O. W., Donaldson G. C., Narayana J. K., et al., “Accelerated Lung Function Decline and Mucus‐Microbe Evolution in Chronic Obstructive Pulmonary Disease,” American Journal of Respiratory and Critical Care Medicine 210, no. 3 (2024): 298–310, 10.1164/rccm.202306-1060OC.
51. van Rossem I., Hanon S., Verbanck S., and Vanderhelst E., “Blood Eosinophil Counts in Chronic Obstructive Pulmonary Disease: Adding Within‐Day Variability to the Equation,” American Journal of Respiratory and Critical Care Medicine 205 (2022): 727–729.
52. Van Rossem I., Hanon S., Vansintejan J., Verbanck S., and Vanderhelst E., “Is Fractional Exhaled Nitric Oxide Ready to Be a Biomarker? Within‐Day Variability in Stable COPD,” Respirology 29, no. 9 (2024): 835–837, 10.1111/resp.14786.
53. Bhatt S. P., Rabe K. F., Hanania N. A., et al., “Dupilumab for COPD With Type 2 Inflammation Indicated by Eosinophil Counts,” New England Journal of Medicine 389 (2023): 205–214.
54. Bhatt S. P., Rabe K. F., Hanania N. A., et al., “Dupilumab for COPD With Blood Eosinophil Evidence of Type 2 Inflammation,” New England Journal of Medicine 390 (2024): 2274–2283.
55. McDonald V. M. and Gibson P. G., “Treatable Traits‐Where We Are, Where We Are Headed,” Respirology 29 (2024): 539–541.
56. McDonald V. M. and Holland A. E., “Treatable Traits Models of Care,” Respirology 29 (2024): 24–35.
57. Srikanthan K., Kistemaker L., Slebos D.‐J., et al., “Targeted Lung Denervation Modulates the Mucosal Epithelial Transcriptome in COPD,” ERJ Open Research 8, no. 4 (2022): 00146–02022, 10.1183/23120541.00146-2022
58. Hartman J. E., Herth F. J. F., Shah P., et al., “Computed Tomographic Airway Morphology After Targeted Lung Denervation Treatment in COPD,” Respiratory Medicine 206 (2023): 107059, 10.1016/j.rmed.2022.107059.
59. Dharmage S. C., Faner R., and Agustí A., “Treatable Traits in Pre‐COPD: Time to Extend the Treatable Traits Paradigm Beyond Established Disease,” Respirology 29 (2024): 551–562.
60. Pavord I. D., Chanez P., Criner G. J., et al., “Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease,” New England Journal of Medicine 377 (2017): 1613–1629.
61. Criner G. J., Celli B. R., Brightling C. E., et al., “Benralizumab for the Prevention of COPD Exacerbations,” New England Journal of Medicine 381 (2019): 1023–1034.
62. Haldar K., Mistry V., Richardson M., et al., “Effect of Benralizumab Treatment on the Airway Microbiome in COPD,” ERJ Open Research 11, no. 2 (2025): 00802‐2024, 10.1183/23120541.00802-2024.
63. Ramakrishnan S., Russell R. E. K., Mahmood H. R., et al., “Treating Eosinophilic Exacerbations of Asthma and COPD With Benralizumab (ABRA): A Double‐Blind, Double‐Dummy, Active Placebo‐Controlled Randomised Trial,” Lancet Respiratory Medicine 13 (2025): 59–68.
64. Bhatt S. P., Rabe K. F., Hanania N. A., et al., “Dupilumab for Chronic Obstructive Pulmonary Disease With Type 2 Inflammation: A Pooled Analysis of Two Phase 3, Randomised, Double‐Blind, Placebo‐Controlled Trials,” Lancet Respiratory Medicine 13 (2025): 234–243.
65. Singh D., Brightling C. E., Rabe K. F., et al., “Efficacy and Safety of Tezepelumab Versus Placebo in Adults With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COURSE): A Randomised, Placebo‐Controlled, Phase 2a Trial,” Lancet Respiratory Medicine 13, no. 1 (2025): 47–58, 10.1016/S2213-2600(24)00324-2.
66. Rabe K. F., Celli B. R., Wechsler M. E., et al., “Safety and Efficacy of Itepekimab in Patients With Moderate‐To‐Severe COPD: A Genetic Association Study and Randomised, Double‐Blind, Phase 2a Trial,” Lancet Respiratory Medicine 9 (2021): 1288–1298.
67. Yousuf A. J., Mohammed S., Carr L., et al., “Astegolimab, an Anti‐ST2, in Chronic Obstructive Pulmonary Disease (COPD‐ST2OP): A Phase 2a, Placebo‐Controlled Trial,” Lancet Respiratory Medicine 10 (2022): 469–477.
68. Singh D., Guller P., Reid F., et al., “A Phase 2a Trial of the IL‐33 mAb Tozorakimab in Patients With COPD: FRONTIER‐4,” European Respiratory Journal (2025): 2402231, 10.1183/13993003.02231-2024.
69. Wang Z., Qiu Y., Ji X., and Dong L., “Effects of Smoking Cessation on Individuals With COPD: A Systematic Review and Meta‐Analysis,” Frontiers in Public Health 12 (2024): 1433269.
70. Siegel S. D., Lerman C., Flitter A., and Schnoll R. A., “The Use of the Nicotine Metabolite Ratio as a Biomarker to Personalize Smoking Cessation Treatment: Current Evidence and Future Directions,” Cancer Prevention Research 13 (2020): 261–272.
71. Qin R., Liu Z., Cheng A.‐q., et al., “Efficacy of Varenicline or Bupropion and Its Association With Nicotine Metabolite Ratio Among Smokers With COPD,” Respirology 29, no. 6 (2024): 479–488, 10.1111/resp.14702.
72. Cinciripini P. M., Green C. E., Shete S., et al., “Smoking Cessation After Initial Treatment Failure With Varenicline or Nicotine Replacement: A Randomized Clinical Trial,” Journal of the American Medical Association 331 (2024): 1722–1731.
73. Rungruanghiranya S., Tulatamakit S., Chittawatanarat K., et al., “Efficacy and Safety of Cytisine Versus Nortriptyline for Smoking Cessation: A Multicentre, Randomized, Double‐Blinded and Placebo‐Controlled Trial,” Respirology 29 (2024): 880–887.
74. Livingstone‐Banks J., Fanshawe T. R., Thomas K. H., et al., “Nicotine Receptor Partial Agonists for Smoking Cessation,” Cochrane Database of Systematic Reviews 5, no. 5 (2023): Cd006103, 10.1002/14651858.CD006103.pub8.
75. Puljević C., Stjepanović D., Meciar I., et al., “Systematic Review and Meta‐Analyses of Cytisine to Support Tobacco Cessation,” Addiction 119 (2024): 1713–1725.
76. Auer R., Schoeni A., Humair J. P., et al., “Electronic Nicotine‐Delivery Systems for Smoking Cessation,” New England Journal of Medicine 390 (2024): 601–610.
77. Allbright K., Villandre J., Crotty Alexander L. E., et al., “The Paradox of the Safer Cigarette: Understanding the Pulmonary Effects of Electronic Cigarettes,” European Respiratory Journal 63 (2024): 2301494
78. Caponnetto P., Campagna D., Ahluwalia J. S., et al., “Varenicline and Counseling for Vaping Cessation: A Double‐Blind, Randomized, Parallel‐Group, Placebo‐Controlled Trial,” BMC Medicine 21 (2023): 220.
79. Caponnetto P., Spicuzza L., Campagna D., et al., “Varenicline for Smoking Cessation in Individuals Who Smoke Cigarettes and Use Electronic Cigarettes: A Double‐Blind, Randomised, Placebo‐Controlled Phase 3 Trial,” EClinicalMedicine 66 (2023): 102316.
80. Ran B., Zhang Y., Wu Y., and Wen F., “Association Between Depression and COPD: Results From the NHANES 2013‐2018 and a Bidirectional Mendelian Randomization Analysis,” Expert Review of Respiratory Medicine 17 (2023): 1061–1068.
81. Sharma P., Scheffer K., Louis M., Aitken C. R., Adams L., and Morris N. R., “Effect of Experimental Modulation of Mood on Exertional Dyspnoea in Chronic Obstructive Pulmonary Disease,” Respirology 29 (2024): 201–208.
82. Pascoe A. and Smallwood N., “Breaking the Spiral: How Negative Mood Can Fuel Exertional Breathlessness in People With Chronic Obstructive Pulmonary Disease,” Respirology 29 (2024): 193–194.
83. Higginson I. J., Brown S. T., Oluyase A. O., et al., “Mirtazapine to Alleviate Severe Breathlessness in Patients With COPD or Interstitial Lung Diseases (BETTER‐B): An International, Multicentre, Double‐Blind, Randomised, Placebo‐Controlled, Phase 3 Mixed‐Method Trial,” Lancet Respiratory Medicine 12 (2024): 763–774.
84. Meneses‐Echavez J. F., Chavez Guapo N., Loaiza‐Betancur A. F., Machado A., and Bidonde J., “Pulmonary Rehabilitation for Acute Exacerbations of COPD: A Systematic Review,” Respiratory Medicine 219 (2023): 107425.
85. Muñoz Montiel A., Ruiz‐Esteban P., Del Doménech Río A., Valdivielso P., Sánchez Chaparro M., and Olveira C., “The Effect of Pulmonary Rehabilitation on Cardiovascular Risk, Oxidative Stress and Systemic Inflammation in Patients With COPD,” Respiratory Medicine 232 (2024): 107740.
86. van der Molen M. C., Posthuma R., Hartman J. E., et al., “Impact and Timing of Pulmonary Rehabilitation in Patients Undergoing Bronchoscopic Lung Volume Reduction With Endobronchial Valves: A Multicentre Randomized Controlled Trial in Patients With Severe Emphysema,” Respirology 29 (2024): 694–703.
87. Strange C. and Talley M., “Winning the Tour de France With Endobronchial Valve Therapy Without Pulmonary Rehabilitation,” Respirology 29 (2024): 651–652.
88. Cranston J. M., Crockett A. J., Moss J. R., and Alpers J. H., “Domiciliary Oxygen for Chronic Obstructive Pulmonary Disease,” Cochrane Database of Systematic Reviews 2005 (2005): Cd001744.
89. García‐Talavera I., Figueira‐Gonçalves J. M., Esteban C., et al., “Oxygen Therapy Could Improve Survival in Patients With Early Desaturation in the 6‐Minute Walk Test: A Post Hoc Analysis,” Respirology 29 (2024): 340–343.
90. Cobb K., Kenyon J., Lu J., et al., “COPD Is Associated With Increased Cardiovascular Disease Risk Independent of Phenotype,” Respirology 29 (2024): 1047–1057.
91. Cochrane B., “COPD: The Forgotten Cardiovascular Risk,” Respirology 29 (2024): 1013–1014.
92. Marin J. M., Soriano J. B., Marin‐Oto M., et al., “Sleep‐Disordered Breathing in Patients With COPD: Prevalence and Outcomes,” Annals of the American Thoracic Society (2025), 10.1513/AnnalsATS.202501-030OC
93. Zhang X., Gray A. R., and Hancox R. J., “Predictors of Lung Function in Early Adulthood: A Population‐Based Cohort Study,” Respirology 29 (2024): 897–904.
94. Garcia‐Aymerich J. and Peralta G. P., “Childhood Physical Inactivity and Excess Weight: Two Potentially Modifiable Risk Factors for COPD,” Respirology 29 (2024): 856–857.
95. Ruane L. E., Denton E., Bardin P. G., and Leong P., “Dysfunctional Breathing or Breathing Pattern Disorder: New Perspectives on a Common but Clandestine Cause of Breathlessness,” Respirology 29 (2024): 863–866.
96. van Dixhoorn J. and Duivenvoorden H. J., “Efficacy of Nijmegen Questionnaire in Recognition of the Hyperventilation Syndrome,” Journal of Psychosomatic Research 29 (1985): 199–206.
97. Law N., Ruane L. E., Low K., Hamza K., and Bardin P. G., “Dysfunctional Breathing Is More Frequent in Chronic Obstructive Pulmonary Disease Than in Asthma and in Health,” Respiratory Physiology & Neurobiology 247 (2018): 20–23